Endra Life Sciences Inc. earnings releases NDRA

Endra Life Sciences Inc. last reported quarterly results on Aug 17, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of $0.06. It usually reports 9–48 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 16, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–48 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 17, 2026
48 days after quarter end
Q2 FY2026
ended Jun 30, 2026
—
0
+113.0%
0.06
Jul 9, 2025
9 days after quarter end
Q2 FY2025
ended Jun 30, 2025
—
-1
+45.0%
—
May 15, 2025
45 days after quarter end
Q1 FY2025
ended Mar 31, 2025
—
-1
+62.7%
—
Nov 15, 2024
46 days after quarter end
Q3 FY2024
ended Sep 30, 2024
—
-2
+24.1%
—
Aug 23, 2024
54 days after quarter end
—
ended Jun 30, 2024
—
—
—
May 10, 2024
40 days after quarter end
—
ended Mar 31, 2024
—
—
—
Nov 14, 2023
45 days after quarter end
—
ended Sep 30, 2023
—
—
—
Aug 14, 2023
45 days after quarter end
—
ended Jun 30, 2023
—
—
—

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
NDRA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Ann Arbor, MI
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1681682
Former names
Endra Inc. (until Sep 21, 2016)

Other Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.